Moreover, the anti-growth effect of TRIM22, which was observed in subcutaneous xenograft experiments, can be reversed by the upregulation of Smad2, indicating that TRIM22 suppressed gastric cancer progression by blocking the TGF-β/Smad pathway [119]. The gene discussed is TGFB1; the disease is gastric cancer.